TYRA Stock Overview
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer.
Tyra Biosciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$12.14|
|52 Week High||US$31.36|
|52 Week Low||US$4.93|
|1 Month Change||25.80%|
|3 Month Change||48.41%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-53.31%|
Recent News & Updates
Tyra Biosciences GAAP EPS of -$0.36
Tyra Biosciences press release (NASDAQ:TYRA): Q2 GAAP EPS of -$0.36. As of June 30, 2022, TYRA had cash and cash equivalents of $275.1 million.
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
|TYRA||US Biotechs||US Market|
Return vs Industry: Insufficient data to determine how TYRA performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how TYRA performed against the US Market.
|TYRA Average Weekly Movement||16.7%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: TYRA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: TYRA's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers.
Tyra Biosciences Fundamentals Summary
|TYRA fundamental statistics|
Is TYRA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TYRA income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.12|
|Net Profit Margin||0.00%|
How did TYRA perform over the long term?See historical performance and comparison
Is TYRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TYRA?
Other financial metrics that can be useful for relative valuation.
|What is TYRA's n/a Ratio?|
Price to Book Ratio vs Peers
How does TYRA's PB Ratio compare to its peers?
|TYRA PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
BLUE bluebird bio
ARCT Arcturus Therapeutics Holdings
MGTX MeiraGTx Holdings
TYRA Tyra Biosciences
Price-To-Book vs Peers: TYRA is good value based on its Price-To-Book Ratio (1.8x) compared to the peer average (3.2x).
Price to Earnings Ratio vs Industry
How does TYRA's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: TYRA is good value based on its Price-To-Book Ratio (1.8x) compared to the US Biotechs industry average (2x)
Price to Book Ratio vs Fair Ratio
What is TYRA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||1.8x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate TYRA's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of TYRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate TYRA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TYRA's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Tyra Biosciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TYRA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TYRA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TYRA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TYRA is forecast to have no revenue next year.
High Growth Revenue: TYRA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TYRA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Tyra Biosciences performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: TYRA is currently unprofitable.
Growing Profit Margin: TYRA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TYRA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare TYRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TYRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: TYRA has a negative Return on Equity (-16.67%), as it is currently unprofitable.
Discover strong past performing companies
How is Tyra Biosciences's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: TYRA's short term assets ($277.3M) exceed its short term liabilities ($5.5M).
Long Term Liabilities: TYRA's short term assets ($277.3M) exceed its long term liabilities ($2.8M).
Debt to Equity History and Analysis
Debt Level: TYRA is debt free.
Reducing Debt: TYRA has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TYRA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: TYRA has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 78.1% each year.
Discover healthy companies
What is Tyra Biosciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TYRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TYRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TYRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TYRA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TYRA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Todd Harris (43 yo)
Dr. Todd Harris, Ph D., serves as President, Chief Executive Officer and Secretary at Tyra Biosciences, Inc. since November, 2018 and serves as its Treasurer since February 2019. Dr. Harris serves as a Dir...
CEO Compensation Analysis
Compensation vs Market: Todd's total compensation ($USD6.38M) is above average for companies of similar size in the US market ($USD2.53M).
Compensation vs Earnings: Todd's compensation has increased whilst the company is unprofitable.
Experienced Management: TYRA's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: TYRA's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: TYRA only recently listed within the past 12 months.
Tyra Biosciences, Inc.'s employee growth, exchange listings and data sources
- Name: Tyra Biosciences, Inc.
- Ticker: TYRA
- Exchange: NasdaqGS
- Founded: 2018
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$505.035m
- Shares outstanding: 41.60m
- Website: https://www.tyra.bio
Number of Employees
- Tyra Biosciences, Inc.
- 2656 State Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/16 00:00|
|End of Day Share Price||2022/08/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.